Eloxx Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - March 16, 2018

Attached files

file filename
EX-10.15 - EX-10.15 - Eloxx Pharmaceuticals, Inc.d542149dex1015.htm
10-K - 10-K - Eloxx Pharmaceuticals, Inc.d542149d10k.htm
EX-32.2 - EX-32.2 - Eloxx Pharmaceuticals, Inc.d542149dex322.htm
EX-32.1 - EX-32.1 - Eloxx Pharmaceuticals, Inc.d542149dex321.htm
EX-31.2 - EX-31.2 - Eloxx Pharmaceuticals, Inc.d542149dex312.htm
EX-31.1 - EX-31.1 - Eloxx Pharmaceuticals, Inc.d542149dex311.htm
EX-21.1 - EX-21.1 - Eloxx Pharmaceuticals, Inc.d542149dex211.htm
EX-10.31 - EX-10.31 - Eloxx Pharmaceuticals, Inc.d542149dex1031.htm
EX-10.29 - EX-10.29 - Eloxx Pharmaceuticals, Inc.d542149dex1029.htm
EX-10.28 - EX-10.28 - Eloxx Pharmaceuticals, Inc.d542149dex1028.htm
EX-10.27 - EX-10.27 - Eloxx Pharmaceuticals, Inc.d542149dex1027.htm
EX-10.26 - EX-10.26 - Eloxx Pharmaceuticals, Inc.d542149dex1026.htm
EX-10.25 - EX-10.25 - Eloxx Pharmaceuticals, Inc.d542149dex1025.htm
EX-10.24 - EX-10.24 - Eloxx Pharmaceuticals, Inc.d542149dex1024.htm
EX-10.20 - EX-10.20 - Eloxx Pharmaceuticals, Inc.d542149dex1020.htm
EX-10.19 - EX-10.19 - Eloxx Pharmaceuticals, Inc.d542149dex1019.htm
EX-10.13 - EX-10.13 - Eloxx Pharmaceuticals, Inc.d542149dex1013.htm
EX-10.12 - EX-10.12 - Eloxx Pharmaceuticals, Inc.d542149dex1012.htm
EX-10.11 - EX-10.11 - Eloxx Pharmaceuticals, Inc.d542149dex1011.htm
EX-10.10 - EX-10.10 - Eloxx Pharmaceuticals, Inc.d542149dex1010.htm
EX-10.9 - EX-10.9 - Eloxx Pharmaceuticals, Inc.d542149dex109.htm
EX-10.8 - EX-10.8 - Eloxx Pharmaceuticals, Inc.d542149dex108.htm
EX-10.7 - EX-10.7 - Eloxx Pharmaceuticals, Inc.d542149dex107.htm
EX-10.6 - EX-10.6 - Eloxx Pharmaceuticals, Inc.d542149dex106.htm
EX-10.5 - EX-10.5 - Eloxx Pharmaceuticals, Inc.d542149dex105.htm
EX-10.4 - EX-10.4 - Eloxx Pharmaceuticals, Inc.d542149dex104.htm
EX-10.3 - EX-10.3 - Eloxx Pharmaceuticals, Inc.d542149dex103.htm
EX-10.2 - EX-10.2 - Eloxx Pharmaceuticals, Inc.d542149dex102.htm
EX-10.1 - EX-10.1 - Eloxx Pharmaceuticals, Inc.d542149dex101.htm
EX-4.1 - EX-4.1 - Eloxx Pharmaceuticals, Inc.d542149dex41.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements on Form S-8 dated January 10, 2018 of our report relating to the consolidated financial statements of Eloxx Pharmaceuticals, Inc. (the “Company”), appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2017.

 

Tel Aviv, Israel  

/s/ KOST FORER GABBAY & KASIERER

March 16, 2018  

KOST FORER GABBAY & KASIERER

A member of Ernst & Young Global

Eloxx Pharmaceuticals, Inc. Reports